Currently available vaccines against severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) are highly effective but not able to keep the coronavirus disease 2019 …

Abstract Background Coronavirus-like particles (CoVLP) that are produced in plants and
display the prefusion spike glycoprotein of the original strain of severe acute respiratory …

Coronavirus disease (Covid-19) has not only shaped awareness of the impact of infectious
diseases on global health. It has also provided instructive lessons for better prevention …

The waning humoral immunity and emerging contagious severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) variants resulted in the necessity of the booster vaccination of …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Several vaccine candidates for COVID-19 have been developed, and few vaccines received
emergency approval with an acceptable level of efficacy and safety. We herein report the …

Currently approved vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have focused solely on the spike protein to provide immunity. The first …

Global COVID-19 vaccine equity remains aspirational for much of the world. But the
emergence of rapidly evolving SARS-CoV-2 variants provides new opportunities to correct …

Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …

Vaccines are one of the most effective strategies to prevent pathogen-induced illness in
humans. The earliest vaccines were based on live inoculations with low doses of live or …